Piramal Pharma Swings to Profit in Q2 FY27 as Revenue Rises 28%
The company reported Rs 2,617 crore in Q2 revenue and raised its FY27 revenue growth outlook to 19% to 20%.
Key Takeaways
- Q2 FY27 revenue was Rs 2,617 crore, up 28% from Rs 2,044 crore.
- Net profit was about Rs 5 crore, against a loss of about Rs 99 crore in Q2 FY26.
- H1 FY27 revenue was Rs 4,887 crore, up 23%, with a net loss of Rs 64 crore.
- CDMO revenue grew 36%, hospital generics 32% and consumer healthcare 13% in Q2.
- The company now expects FY27 revenue growth of 19% to 20%.
Piramal Pharma swung to a net profit of about Rs 5 crore in the September 2026 quarter (Q2 FY27), against a net loss of about Rs 99 crore a year earlier. Its revenue from operations rose 28% to Rs 2,617 crore, from Rs 2,044 crore in Q2 FY26.
For the first half of FY27 (H1), the company reported revenue of Rs 4,887 crore, up 23% from Rs 3,977 crore, and a net loss of Rs 64 crore, narrower than the Rs 181 crore loss in H1 FY26. The company announced the results on 27 October 2026 and raised its outlook for the full year.
Piramal Pharma Q2 and H1 FY27 at a glance
| Detail | Piramal Pharma |
|---|---|
| Q2 FY27 revenue from operations | Rs 2,617 crore, up 28% from Rs 2,044 crore |
| Q2 FY27 net profit | About Rs 5 crore, against a loss of about Rs 99 crore in Q2 FY26 |
| H1 FY27 revenue from operations | Rs 4,887 crore, up 23% from Rs 3,977 crore |
| H1 FY27 net loss | Rs 64 crore, against Rs 181 crore in H1 FY26 |
| Quarter and half year ended | 30 September 2026 |
| FY27 revenue growth outlook | 19% to 20%, raised by the company |
How the CDMO, hospital generics and consumer businesses grew in Q2
Piramal Pharma works in three areas. Its contract development and manufacturing (CDMO) business makes drugs and drug ingredients for other pharma companies. Complex Hospital Generics (CHG) sells hospital products such as inhalation anesthesia.
In Q2 FY27, CDMO revenue grew 36%, CHG revenue grew 32% and PCH revenue grew 13% from a year earlier. The company said the Kenalog portfolio contributed to CHG revenue in the quarter.
| Business | Q2 FY27 revenue growth |
|---|---|
| CDMO | 36% |
| Complex Hospital Generics | 32% |
| Piramal Consumer Healthcare | 13% |
Three quarters of Piramal Pharma's revenue and profit, side by side
| Quarter | Revenue and result |
|---|---|
| Q2 FY26 (September 2025 quarter) | Revenue Rs 2,044 crore; net loss about Rs 99 crore |
| Q1 FY27 (June 2026 quarter) | Revenue about Rs 2,270 crore, up 17%; net loss about Rs 69 crore |
| Q2 FY27 (September 2026 quarter) | Revenue Rs 2,617 crore, up 28%; net profit about Rs 5 crore |
What Piramal Pharma said about the rest of FY27
In its results release, the company said that based on its strong first-half performance it now expects revenue growth of 19% to 20% in FY27, with meaningfully higher profitability.
Where Piramal Pharma stands after its first profitable quarter of the year
Piramal Pharma started FY27 with a net loss of about Rs 69 crore in Q1 and moved to a profit of about Rs 5 crore in Q2. Its revenue for the first half stands at Rs 4,887 crore, up 23% from a year earlier. The company has said it expects FY27 revenue growth of 19% to 20%.
More news
Frequently Asked Questions
What is Piramal Pharma?
How much revenue did Piramal Pharma report in Q2 FY27?
How much profit did Piramal Pharma make in Q2 FY27?
How did Piramal Pharma do in the first half of FY27?
How much did Piramal Pharma's CDMO business grow in Q2 FY27?
How much did Piramal Pharma's hospital generics business grow in Q2?
How much did Piramal Consumer Healthcare grow in Q2 FY27?
What is Piramal Pharma's FY27 revenue growth outlook?
When did Piramal Pharma announce its Q2 and H1 FY27 results?
What period do Piramal Pharma's Q2 FY27 results cover?
What was Piramal Pharma's result in Q1 FY27?
How much revenue did Piramal Pharma report in Q2 FY26?
More in Business
Info Edge Names Sanjeev Bikhchandani Group CEO From December
Info Edge founder Sanjeev Bikhchandani has been named Group CEO, subject to shareholder approval, as Hitesh Oberoi steps down.
Info Edge Q2 Profit Rises 87% to About Rs 650 Crore
Info Edge also declared a Rs 3 per share interim dividend with its September quarter results.
LTM Launches GCC Origin Unit to Build and Run GCCs in India
LTM has launched GCC Origin, a unit that builds and runs global capability centres in India.